Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2

References

• Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332:581–588.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383–392.
   PubMed Web of Science ®Google Scholar
• Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899–1912.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: Epidemiology, clinical features, course and outcome. Ann Rheum Dis. 2006;64(suppl II):ii14–17.
   Google Scholar
• Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emmanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47:512–518.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life in 369 patients. Br J Dermatol. 1995;132:236–244.
   PubMed Web of Science ®Google Scholar
• Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther. 2008;21:54–59.
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB Jr, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17:24–28.
   PubMed Web of Science ®Google Scholar
• Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213:102–110.
   PubMed Web of Science ®Google Scholar
• Chan B, Hales B, Shear N, Ho V, Lynde C, Poulin Y, Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg. 2009;13:192–197.
   PubMed Web of Science ®Google Scholar
• Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59:772–780.
   PubMed Web of Science ®Google Scholar
• Horn EJ, Fox KM, Patel V, Chiou C-F, Dann F, Lebwohl M. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007;57:963–971.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Kimball AB, Krueger GG, Wooley JM, Lalla D, Jahreis A. Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial. J Am Acad Dermatol. 2005;53:887–889.
   PubMed Web of Science ®Google Scholar
• Krueger GC, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Patient-reported outcomes of psoriasis improvement with etanercept therapy: Results of a randomized phase III trial. Br J Dermatol. 2005;153:1192–1199.
   PubMed Web of Science ®Google Scholar
• Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis. Am J Clin Dermatol. 2003;4:131–139.
   PubMed Web of Science ®Google Scholar
• Menter A. The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy. J Cutan Med Surg. 2004;8(suppl 2):20–25.
   Google Scholar
• Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol. 2004;150:317–326.
   PubMed Web of Science ®Google Scholar
• Menter A, Kosinki M, Bresnahan BW, Papp KA, Ware JE Jr. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol. 2004;3:27–38.
   PubMedGoogle Scholar
• Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: Patient-reported outcomes from a Phase II randomized clinical trial. J Dermatol Treat. 2007;18:25–31.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatol Treat. 2007;18:341–350.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, Ortonne J-P, Wu Y, Bala M, Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: A randomised controlled trial. Br J Dermatol. 2006;154:1161–1168.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Gottlieb AB, Bala M. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159:704–710.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Infliximab improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol. 2007;17:381–386.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol. 2006;33:2254–2259.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–1674.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–1684.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: Results from the PHOENIX 1 trial. Br J Dermatol. 2010;162:137–146.
   PubMed Web of Science ®Google Scholar
• Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu M-C, Ustekinumab significantly improves symptoms of anxiety, depression, and quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled Phase III trial. J Am Acad Dermatol. Published online May 10, 2010. doi:10.1016/j.jaad.2009.09.014.
   Google Scholar
• Lerner D, Amick BC III, Rogers WH, Malspeis S, Bungay K, Cynn D. The work limitations questionnaire. Med Care. 2001;39:72–85.
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370.
   PubMed Web of Science ®Google Scholar
• Bjelland L, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale: An updated literature review. J Psychosom Res. 2002;52:69–77.
   PubMed Web of Science ®Google Scholar
• Snaith RP, Zigmond AS. The Hospital Anxiety and Depression Scale Manual. Windsor, UK: NFER Nelson; 1994.
   Google Scholar
• Herrmann C. International experiences with the Hospital Anxiety and Depression Scale – A review of validation data and clinical results. J Psychosom Res. 1997;42:17–41.
   PubMed Web of Science ®Google Scholar
• Allaire S, Wolfe F, Niu J, Lavalley M, Michaud K. Work disability and its economic effects on 55- to 64-year-old adults with rheumatoid arthritis. Arthritis Rheum. 2005;53:603–608.
   PubMedGoogle Scholar
• Lerner D, Reed JI, Massarotti E, Wester LM, Burke TA. The Work Limitations Questionnaire's validity and reliability among patients with osteoarthritis. J Clin Epidemiol. 2002;55:197–208.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI). Clin Exp Dermatol. 1994;19:210–216.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis – Oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
   PubMedGoogle Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care. 2003;41:582–592.
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc.; 1988.
   Google Scholar
• Wakkee M, Nijsten T. Comorbidities in dermatology. Dermatol Clin. 2009;27:137–147.
   Google Scholar
• Reich K, Han C, Szapary P, Yeilding N, Ortonne J-P, Schenkel B, Impact of depression and anxiety on employability and productivity in patients with moderate to severe psoriasis. Br J Dermatol. 2008;159:1424.
   Google Scholar
• Lerner D, Amick BC III, Lee JC, Rooney T, Rogers WH, Chang H, Relationship of employee-reported work limitations to work productivity. Med Care. 2003;41:649–659.
   PubMed Web of Science ®Google Scholar
• Adler DA, Irish J, McLaughlin TJ, Perissinotto C, Chang H, Hood M, The work impact of dysthymia in a primary care population. Gen Hosp Psychiatry. 2004;26:269–276.
   Google Scholar
• Lerner D, Adler DA, Chang H, Berndt ER, Irish JT, Lapitsky L, The clinical and occupational correlates of work productivity loss among employed patients with depression. J Occup Environ Med. 2004;46:S46–55.
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Han C, DeVlam K, Burmester G, Van den Bosch F, Williamson P, Infliximab improves productivity and reduces work day loss in patients with ankylosing spondylitis: Results from a randomized, placebo-controlled trial. Arthritis Rheum. 2006;55:569–574.
   PubMed Web of Science ®Google Scholar